Cargando…

420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial

OBJECTIVES/GOALS: Reduced cerebral blood flow (CBF) along with vascular risk factors (e.g., dyslipidemia) are prevalent in Alzheimers disease (AD) and related dementias. Statins are one of the most effective pharmacologic treatments for vascular risk reduction, which may contribute to CBF in individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Aaron, Stacey E., Tomoto, Tsubasa, Zhang, Rong, Billinger, Sandra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209253/
http://dx.doi.org/10.1017/cts.2022.244
_version_ 1784729908743766016
author Aaron, Stacey E.
Tomoto, Tsubasa
Zhang, Rong
Billinger, Sandra A.
author_facet Aaron, Stacey E.
Tomoto, Tsubasa
Zhang, Rong
Billinger, Sandra A.
author_sort Aaron, Stacey E.
collection PubMed
description OBJECTIVES/GOALS: Reduced cerebral blood flow (CBF) along with vascular risk factors (e.g., dyslipidemia) are prevalent in Alzheimers disease (AD) and related dementias. Statins are one of the most effective pharmacologic treatments for vascular risk reduction, which may contribute to CBF in individuals with an increased risk for AD. METHODS/STUDY POPULATION: Cross-sectional analysis of 212 older adults with a family history of dementia. Heart rate via electrocardiogram, mean arterial pressure (MAP) via brachial sphygmomanometers, end-tidal CO2 via capnograph, and CBF velocity at the middle cerebral artery (MCAv) via transcranial Doppler ultrasound were collected following 20-minutes of supine rest. Mean MCAv (cm/s) was measured within each cardiac cycle and averaged over an 8-minute duration. Cerebrovascular conductance was calculated by dividing mean MCAv by MAP. Pulsatility Index was calculated by subtracting systolic MCAv from diastolic MCAv and then dividing by mean MCAv. RESULTS/ANTICIPATED RESULTS: 125 females (68 ± 6 years; 49 statin) and 87 males (70 ± 6 years; 47 statin) were included in analyses. There were no significant differences between heart rate, MAP, or end-tidal CO2 between statin and non-statin users. After controlling for age, sex, and low-density and high-density lipoprotein, statin use did not significantly contribute to MCAv (p = 0.09). However, statin use did significantly contribute to cerebrovascular conductance (MCAv/MAP; p = 0.03) as well as Pulsatility Index (assessment of cerebral health, p < 0.01). DISCUSSION/SIGNIFICANCE: Our findings suggest statin use significantly and positively contributes to resting cerebral blood flow velocity and cerebrovascular health. Further investigation is warranted into statin interventions with other components of cerebrovascular function, as differences may have implications for brain health and disease pathogenesis.
format Online
Article
Text
id pubmed-9209253
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-92092532022-07-01 420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial Aaron, Stacey E. Tomoto, Tsubasa Zhang, Rong Billinger, Sandra A. J Clin Transl Sci Valued Approaches OBJECTIVES/GOALS: Reduced cerebral blood flow (CBF) along with vascular risk factors (e.g., dyslipidemia) are prevalent in Alzheimers disease (AD) and related dementias. Statins are one of the most effective pharmacologic treatments for vascular risk reduction, which may contribute to CBF in individuals with an increased risk for AD. METHODS/STUDY POPULATION: Cross-sectional analysis of 212 older adults with a family history of dementia. Heart rate via electrocardiogram, mean arterial pressure (MAP) via brachial sphygmomanometers, end-tidal CO2 via capnograph, and CBF velocity at the middle cerebral artery (MCAv) via transcranial Doppler ultrasound were collected following 20-minutes of supine rest. Mean MCAv (cm/s) was measured within each cardiac cycle and averaged over an 8-minute duration. Cerebrovascular conductance was calculated by dividing mean MCAv by MAP. Pulsatility Index was calculated by subtracting systolic MCAv from diastolic MCAv and then dividing by mean MCAv. RESULTS/ANTICIPATED RESULTS: 125 females (68 ± 6 years; 49 statin) and 87 males (70 ± 6 years; 47 statin) were included in analyses. There were no significant differences between heart rate, MAP, or end-tidal CO2 between statin and non-statin users. After controlling for age, sex, and low-density and high-density lipoprotein, statin use did not significantly contribute to MCAv (p = 0.09). However, statin use did significantly contribute to cerebrovascular conductance (MCAv/MAP; p = 0.03) as well as Pulsatility Index (assessment of cerebral health, p < 0.01). DISCUSSION/SIGNIFICANCE: Our findings suggest statin use significantly and positively contributes to resting cerebral blood flow velocity and cerebrovascular health. Further investigation is warranted into statin interventions with other components of cerebrovascular function, as differences may have implications for brain health and disease pathogenesis. Cambridge University Press 2022-04-19 /pmc/articles/PMC9209253/ http://dx.doi.org/10.1017/cts.2022.244 Text en © The Association for Clinical and Translational Science 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Valued Approaches
Aaron, Stacey E.
Tomoto, Tsubasa
Zhang, Rong
Billinger, Sandra A.
420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial
title 420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial
title_full 420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial
title_fullStr 420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial
title_full_unstemmed 420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial
title_short 420 Comparison of Statin Use to Non-Use on Cerebral Blood Flow Velocity in Older Adults at Risk for Alzheimers Disease: Data from a Phase II Multisite Clinical Trial
title_sort 420 comparison of statin use to non-use on cerebral blood flow velocity in older adults at risk for alzheimers disease: data from a phase ii multisite clinical trial
topic Valued Approaches
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209253/
http://dx.doi.org/10.1017/cts.2022.244
work_keys_str_mv AT aaronstaceye 420comparisonofstatinusetononuseoncerebralbloodflowvelocityinolderadultsatriskforalzheimersdiseasedatafromaphaseiimultisiteclinicaltrial
AT tomototsubasa 420comparisonofstatinusetononuseoncerebralbloodflowvelocityinolderadultsatriskforalzheimersdiseasedatafromaphaseiimultisiteclinicaltrial
AT zhangrong 420comparisonofstatinusetononuseoncerebralbloodflowvelocityinolderadultsatriskforalzheimersdiseasedatafromaphaseiimultisiteclinicaltrial
AT billingersandraa 420comparisonofstatinusetononuseoncerebralbloodflowvelocityinolderadultsatriskforalzheimersdiseasedatafromaphaseiimultisiteclinicaltrial